3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
213
Carcinoma, Non-Small-Cell Lung
148
Lung Neoplasms
128
Lymphoma
119
Prostatic Neoplasms
115
Leukemia
102
Ovarian Neoplasms
100
Central Nervous System Neoplasms
95
Precursor Cell Lymphoblastic Leukemia-Lymphoma
89
Colorectal Neoplasms
89
Head and Neck Neoplasms
87
Sarcoma
84
Multiple Myeloma
80
Squamous Cell Carcinoma of Head and Neck
73
Rectal Neoplasms
62
Leukemia, Myeloid, Acute
62
Carcinoma, Ovarian Epithelial
61
Uterine Cervical Neoplasms
60
Neoplasm Metastasis
59
Brain Neoplasms
57
Colonic Neoplasms
56
Fallopian Tube Neoplasms
53
Astrocytoma
53
Lymphoma, Large B-Cell, Diffuse
50
Glioblastoma
49
Burkitt Lymphoma
47
Urinary Bladder Neoplasms
46
Neuroblastoma
44
Melanoma
44
Hodgkin Disease
44
Interventions
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Triptorelin Pamoate
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Interventional
×
Breast Cancer Invasive Nos
×
Clear all
NCT02005887
2019-05-29
TREND
ETOP IBCSG Partners Foundation
Phase 2
Completed
51 enrolled
10 charts